Euro
USD
British Pound
NULL
Product Description
VHL Antibody | 16-528 | ProSci
Host: Rabbit
Reactivity: Human, Mouse, Rat
Homology: N/A
Immunogen: A synthetic peptide corresponding to a sequence within amino acids 1-100 of human VHL (NP_937799.1) .
Research Area: Apoptosis, Cancer, Cell Cycle, Immunology
Tested Application: WB, IHC
Application: WB: 1:500 - 1:2000
IHC: 1:50 - 1:200
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Observed: 24kDa
Validation: N/A
Isoform: N/A
Purification: Affinity purification
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Concentration: N/A
Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.
Alternate Name: VHL, von Hippel-Lindau tumor suppressor, HRCA1, RCA1, VHL1, elongin binding protein, von Hippel-Lindau syndrome, pVHL
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF) , which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
